EMEA-002183-PIP01-17-M01
Key facts
| Invented name |
Idefirix
|
| Active substance |
Imlifidase
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0076/2022
|
| PIP number |
EMEA-002183-PIP01-17-M01
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Prevention of graft rejection following solid organ transplantation
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Hansa Biopharma AB
E-mail: info@hansabiopharma.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|